Navigation Links
New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain
Date:5/8/2008

Results presented at the 27th Annual Meeting of the American Pain Society

(APS)

SMYRNA, Ga., May 8 /PRNewswire/ -- Patients treated with lacosamide demonstrated sustained pain relief from diabetic neuropathic pain (DNP), compared to placebo-treated patients, according to data presented at the 27th annual meeting of the American Pain Society (APS) in Tampa, Fla.

"This is the first placebo-controlled trial of a diabetic neuropathic pain treatment providing evidence of long-term efficacy for more than one year in a withdrawal setting," said Tibor Hidvegi, MD, Medical Department, Petz Aladar Hospital, Gyor, Hungary. "These results are promising because more treatment options are needed for DNP, a debilitating complication of diabetes that can leave patients in discomfort."

Study Design

This placebo-controlled, withdrawal study was a sub-trial of an open- label, follow-on (SP746) to a Phase III, double-blind trial (SP743). Patients had been followed for at least 16 months (mean 20 months) before entering the sub-trial. Prior to any lacosamide treatment, patients had an average daily pain score of 6.5. After more than a year of open-label treatment, the mean pain score was 2.5, the baseline score of the withdrawal sub-trial.

A total of 106 patients treated with lacosamide (100-400 mg/day) participated in the withdrawal study. In a blinded fashion, lacosamide treatment was withdrawn (less than or equal to 28 days) and reintroduced to these patients.

The primary endpoint was the change in average daily pain score from baseline (seven days prior to randomization) to the last seven days of each period, using the 11-point Likert pain scale, which ranges from zero (no pain) to 10 (worst possible pain).

Study Results

The difference in average daily pain scores between lacosamide and placebo was statistically significant and favored lacosamide (p= 0.007). In addition, average daily pa
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
2. Data Presented at AAN Support Potential for Adjunctive use of Intravenous Lacosamide as Short-Term Replacement for Oral Treatment in Partial Epilepsy
3. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
4. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
5. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
6. Raptor Pharmaceuticals Provides Update of Product Programs
7. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
8. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
9. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
10. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
11. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... HILLS, Calif. , Jan. 14, 2014 The Brandeis Medical ... Los Angeles a premier and affordable laser tattoo removal ... special. Dr. Brandeis, focus is in providing high quality cosmetic services ... all patients. " Southern California has ...
(Date:1/14/2014)... 14, 2014   NuAire , a manufacturer of ergonomically designed ... Hitachi Koki of Japan to sell ... America . NuAire will utilize its network of sales professionals ... Canada to offer assistance in application use, product benefits ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... N.C., Oct. 31 AlphaVax, Inc.,announced today that it ... of an influenza vaccine based on its proprietary replicon ... properties of this,unique vector system as well as the ... was a placebo-controlled, randomized, double-blind trial in,healthy adults, 18-40 ...
... guide low-income,and minority cancer patients through cancer treatment, ... major obstacles that prevent them,from receiving quality care ... October 28, 2007, at the American Society for ... Angeles. Minority and low-income cancer patients continue ...
Cached Medicine Technology:AlphaVax Announces Results From Phase 1 Influenza Vaccine Clinical Trial 2Patient Navigators Help Minority, Low-Income Cancer Patients Get Life-Saving Treatments 2
(Date:7/9/2014)... researchers reveal that sudden, acute episodes of low back ... temperature, humidity, air pressure, wind direction and precipitation. Findings ... journal of the American College of Rheumatology (ACR), indicate ... with higher wind speed or wind gusts, but was ... Health Organization (WHO) nearly everyone experiences low back pain ...
(Date:7/9/2014)... A network of signals active in almost all types ... into overdrive, and may help fuel a tumour,s uncontrolled ... of Cancer Research, London, identified a molecular trigger responsible ... the cellular factory that makes the building blocks ... in the TOR signalling pathway, called SREBP, controls the ...
(Date:7/9/2014)... fecal transplantation is effective and safe for treating ... result of a study led by Colleen Kelly, M.D., ... at The Women,s Medicine Collaborative. The study and its ... in the American Journal of Gastroenterology . , ... has increased to epidemic proportions over the past decade. ...
(Date:7/9/2014)... 9, 2014 There has been a sharp increase ... Medical Center using MyChart, the online, interactive service that ... with their healthcare providers, schedule appointments, and renew prescriptions. ... actively using MyChart each year increased five-fold, ... more than 10-fold, according to a study by ...
(Date:7/9/2014)... Infectious Diseases (NIAID), part of the National Institutes ... of CRS3123, an investigational oral antibiotic intended to ... ) infection. CRS3123 (previously known as REP3123) is ... while sparing normal intestinal bacteria. , The Phase ... men and women ages 18 to 45 in ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2
... and in the care of state institutions, should be ... and treatment, Health// Minister Manto Tshabalala-Msimang said. ... members, at Weskoppies psychiatric hospital, Pretoria, the minister said ... the past that mental health care users could be ...
... access journal Substance Abuse Treatment, Prevention and policy unwinds that ... the alcohol dependent patients better for a long term. ... GPs who abstain from drinking alcohol is more than the ... alone at the medical school. Also the abstinence is ...
... Post Menopausal women with early breast cancer who have ... to a more modern therapy with the drug//, Arimidex ... AstraZeneca. ,The company AstraZeneca has stated that ... women who have already received a partial course of ...
... death of 113 animals associated with the anthrax outbreak ... in Saskatchewan. Spore-forming bacteria that can spread// among animals ... anthrax. ,The Canadian Food Inspection Agency (CFIA) ... animals on farms tested positive for anthrax. However some ...
... claims to have reached, and exceeded, its medical recruitment ... the need// for an additional $5 billion for mental ... planned to employ400 more allied health professionals, 500 more ... ,According to Health Minister Stephen Robertson the ...
... their new studies have concluded that persons who live ... serious heart condition when compared to people// who live ... Melgaard Nielsen, Ph.D., and colleagues, of the Aarhus Sygehus ... on 138,000 adults between the ages of 30-69. Their ...
Cached Medicine News:Health News:Queensland Government to Meet its Medical Targets 2Health News:Significant Increase In Heart Diseases Found In Older People Living Alone 2
... generators are meeting the clinical needs ... and anesthesiologists. And, they are of ... from Medtronic.,Effective pacing with the adjustment ... for quick battery changes. Both ...
... CardioVad is a unique left ventricular assist device ... It is being used in a small group ... as part of an FDA-approved Feasibility Study. The ... the external power source for minutes or hours. ...
... Inc. has introduced the world's first minimally-invasive ... 10626 Epicardial Lead Implant Tool, which has ... States, will expand the options available to ... 5071 lead on the heart during pacemaker ...
The Schiller treadmill ergometer is designed for stress tests, sports medicine and cardiology. It is equipped and tested with the latest safety system and has been manufactured under the stringent qu...
Medicine Products: